Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance

Biomedicine and Pharmacotherapy

Volumn 61, Issue 6, 2007, Pages 347-355

  Brenes, O ^a   Arce, F ^a,b   Gatjens Boniche O ^c   Diaz C ^a  

^a UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^b Hospital Calderon Guardia   (Costa Rica)

^c INSTITUTO TECNOLÓGICO DE COSTA RICA   (Costa Rica)

Author keywords

Apoptosis; Cancer; Chemotherapy; Hepatocellular carcinoma; Survivin

Indexed keywords

CISPLATIN; DNA FRAGMENT; FLUOROURACIL; PACLITAXEL; PROTEIN BAX; PROTEIN BCL XL; SURVIVIN;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG MECHANISM; DRUG RESISTANCE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PACLITAXEL;

EID: 34547549805     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.02.007     Document Type: Article

References (46)

1. Dimanche-Boitrel M.T., Meurette O., Rebillard A., and Lacour S. Role of early plasma membrane events in chemotherapy-induced cell death. Drug Resist Updat 8 (2005) 5-14
2. Leist M., and Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2 (2001) 1-10
3. Lockshin R.A., and Zakeri Z. Caspase-independent cell deaths. Curr Opin Cel Biol 14 (2002) 727-733
4. Bröker L.E., Kruyt F.A.E., and Giaccone G. Cell death independent of caspases: a review. Clin Cancer Res 11 (2005) 3155-3162
5. Igney F.H., and Krammer P.H. Death and anti-death: tumor resistance to apoptosis. Nat Rev Cancer 2 (2002) 277-288
6. Llovet J.M., and Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J Hepatol 38 (2003) S136-S149
7. Murakami Y., Hayashi K., Hirohashi S., and Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 51 (1991) 5520-5525
8. Ng I.O., Chung L.P., Tsang S.W., Lam C.L., Lai E.C., Fan S.T., et al. p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene 9 (1994) 985-990
9. Chi T.Y., Chen G.G., and Lai P.B. Eicosapentaenoic acid induces Fas-mediated apoptosis through a p53-dependent pathway in hepatoma cells. Cancer J 10 (2004) 190-200
10. Hockenbery D.M., Zutter M., Hickey W., Nahm M., and Korsmeyer S.J. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A 88 (1991) 6961-6965
11. Charlotte F.L., Hermine A., Martin N., Geleyn Y., Nollet M., Gaulard P., and Zafrani E.S. Immunohistochemical detection of Bcl-2 protein in normal and pathological human liver. Am J Pathol 144 (1994) 460-465
12. Takehara T., Liu X., Fujimoto J., Friedman S.L., and Takahashi H. Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 34 (2001) 55-61
13. Luo D., Cheng S.C.J., and Xie Y. Effect of Bcl-2 and Bcl-xL protein levels on chemoresistance of hepatoblastoma HepG2 cell line. Biochem Cell Biol 78 (2000) 119-126
14. Linkermann A., Qian J., Lettau M., Kabelitz D., and Janssen O. Considering Fas ligand as a target for therapy. Expert Opin Ther Targets 9 (2005) 119-134
15. Jiang S., Song M.J., Shin E.-C., Lee M.-O., Kim S.J., and Park J.H. Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways. Hepatology 29 (1999) 101-110
16. Muller M.S., Wilder D., Bannasch D., Israeli K., Lehlbach M., Li-Weber S.L., et al. p53 activates the CD95 (APO-1Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188 (1998) 2033-2045
17. You K.R., Shin M.N., Park R.K., Lee S.O., and Kim D.G. Activation of caspase-8 during N-(4-hydroxyphenyl) retinamide-induced apoptosis in Fas-defective hepatoma cells. Hepatology 34 (2001) 1119-1127
18. Arce F., Gätjens-Boniche O., Vargas E., Valverde B., and Díaz C. Apoptotic events induced by naturally occurring retinoids ATRA and 13-cis retinoic acid on human hepatoma cell lines Hep3B and HepG2. Cancer Lett 229 (2005) 271-281
19. Takachima H., Nakajima T., Moriguchi M., Sekoguchi S., Nishikawa T., Watanabe T., et al. In vivo expression patterns of survivin and its splicing variants in chronic liver disease and hepatocellular carcinoma. Liver Int 25 (2005) 77-84
20. Moon W.S., and Tarnawski A.S. Nuclear translocation of survivin in hepatocellular carcinoma: a key to cancer cell growth?. Hum Pathol 34 (2003) 1119-1126
21. Zhang W., Chen X., and Qiu F. An antisense plasmid targeting survivin expression induces apoptosis and sensitizes hepatocarcinoma cells to chemotherapy. J Huazhong Univ Sci Technolog Med Sci 23 (2003) 387-391
22. Leung T.W.T., and Johnson P.J. Systemic therapy for hepatocellular carcinoma. Semin Oncol 28 (2001) 514-520
23. Ocker M., Alajati A., Ganslmayer M., Zopf S., Luders M., Neureiter D., et al. The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol 131 (2005) 384-394
24. Li Y.X., Lin Z.B., and Tan H.R. Wild type p53 increased chemosensitivity of drug-resistant human hepatocellular carcinoma Bel7402/5-FU cells. Acta Pharmacol Sin 25 (2004) 76-82
25. Capri G., Tarenzi E., Fulfaro F., and Gianni L. The role of taxanes in the treatment of breast cancer. Semin Oncol 23 (1996) 68-75
26. Gagandeep S., Novikoff P.M., Ott M., and Gupta S. Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines. Cancer Lett 136 (1999) 109-118
27. Chao Y., Chan W.K., Birkhofer M.J., Hu O.Y., Wang S.S., Huang Y.S., et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 78 (1998) 34-39
28. Wang D., and Lippard S.J. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4 (2005) 307-320
29. Yodono H., Saito Y., Saikawa Y., Midorikawa H., Yokoyama Y., and Takekawa S. Combination chemoembolization therapy for hepatocellular carcinoma: mainly using cisplatin (CDDP). Cancer Chemother Pharmacol 23 (1989) S42-S44
30. Tanioka H., Tsuji A., Morita S., Horimi T., Takamutsu M., Shirasaka T., et al. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 23 (2003) 1891-1897
31. Shirasaka T., Shimamoto Y., Ohshimo H., Saito H., and Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 32 (1993) 167-172
32. Okamura M., Hashimoto K., Shimada J., and Sakagami H. Apoptosis-inducing activity of cisplatin (CDDP) against human hepatoma and oral squamous cell carcinoma cell lines. Anticancer Res 24 (2004) 655-661
33. Perry J.F., Poustchi H., George J., Farrell G.C., McCaughan G.M., and Strasser S.I. Current approaches to the diagnosis and management of hepatocellular carcinoma. Clin Exp Med 5 (2005) 1-13
34. Chun E., and Lee K.Y. Bc.-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 315 (2004) 771-779
35. Kim J.S., Lee J.M., Chwae Y.J., Kim Y.H., Lee J.H., Kim K., et al. Cisplatin-induced apoptosis in Hep3B cells: mitochondria-dependent and -independent pathways. Biochem Pharmacol 67 (2004) 1459-1468
36. Henkels K.M., and Turchi J.J. Cisplatin-induced apoptosis proceeds by caspase-3 dependent and -independent pathways in cisplatin-resistant and sensitive human ovarian cancer cell lines. Cancer Res 59 (1999) 3077-3083
37. Cummings B.S., and Schnellmann R.G. Cisplatin-induced renal cell apoptosis: caspase-3-dependent and -independent pathways. J Pharmacol Exp Ther 302 (2002) 8-17
38. Zhu H., Guo W., Zhang L., Davis J.J., Teraishi F., Wu S., et al. Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther 4 (2005) 451-456
39. Miao J., Chen G.G., Chun S.Y., Chak E.C.W., and Lai P.B.S. Bid sensitizes apoptosis induced by chemotherapeutic drugs in hepatocellular carcinoma. Int J Oncol 25 (2004) 651-659
40. Lu K.-H., Lue K.-H., Liao H.-H., Lin K.-L., and Chung J.-G. Induction of caspase-3-dependent apoptosis in human leukemia HL-60 cells by paclitaxel. Clin Chim Acta 357 (2005) 65-73
41. Fields A.C., Cotsonis G., Sexton D., Santoianni R., and Cohen C. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognosis patterns and outcome. Mod Pathol 17 (2004) 1778-1785
42. Kroemer G., and Jaattela M. Lysosomes and autophagy in cell death control. Nat Rev Cancer 5 (2005) 886-897
43. Altieri D.C. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7 (2001) 542-547
44. Altucci L., and Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 1 (2001) 181-193
45. Muto Y., Moriwaki H., and Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 340 (1999) 1046-1047
46. Okuno M., Sano T., Matsushima-Nishiwaki R., Adachi S., Akita K., Okano Y., et al. Apoptosis induction by acyclic retinoid: a molecular basis of clonal deletion therapy for hepatocellular carcinoma. Jpn J Clin Oncol 3 (2001) 359-362